LivaNova (NSDQ:LIVN) yesterday touted 18-month results from the Respond-CRT trial of its SonR hemodynamic monitor, saying it confirmed the “significant risk reduction in heart failure hospitalization on the overall population enrolled in the study” compared with manual, echocardiography-guided optimization.
Subgroups of patients with atrial fibrillation and renal dysfunction showed a 48% and 41% lower risk of cardiovascular death or hospitalization when treated using the SonR device, the company said.
risk reduction in cardiovascular death or hospitalization was observed with SonR, respectively.
“We are very pleased to observe the consistent long-term clinical benefits of the SonR optimization system,” principal investigator Dr. Josep Brugada, of Spain’s University of Barcelona, said in prepared remarks. “Reduction of hospitalization is key for heart failure patients. The impressive improvements in cardiovascular clinical outcomes for patients with atrial fibrillation or renal dysfunction show that SonR can treat even better the sicker patients.”
“The successful outcomes of the RESPOND-CRT study provides important data that we are pleased to share with the healthcare community,” added CRM general manager Benoît Clinchamps. “LivaNova is committed to developing and delivering safe and effective technology to better treat heart failure patients. The SonR sensor-based optimization system fully resonates with this commitment.”